Drug Trial Radar · NCT06685965
A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep Disturbances
Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Sep 30, 2025
Primary completion
Jun 14, 2026
Study completion Jun 15, 2026
Sponsor
- Lead sponsor
- Reconnect LabsIndustry
- Sponsor type
- Industry
- Collaborators
- University of Zurich
- First posted
- Nov 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Post-traumatic stress disorder (PTSD) affects many people who have experienced traumatic events. A common issue with PTSD is severe sleep disturbances, such as nightmares. Current treatments often do not provide sufficient relief, especially for sleep problems. This study aims to determine whether dexmedetomidine - a medication already used in intensive care - can improve sleep quality in PTSD patients.
Conditions
- Posttraumatic Stress Disorder (PTSD)
- Sleep Disturbances and Insomnia
Interventions
RE03Drug
Buccal Dexmedetomidine
PlaceboDrug
Matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time spent in sleep stages N2 + N3Time frame: 0.5 hours after each substance administration for 9 hours or until terminal morning awakening
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Human Sleep Pharmacology, University of Zurich
Zurich, Canton of Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.